Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome

被引:210
作者
Stetler-Stevenson, M
Arthur, DC
Jabbour, N
Xie, XY
Molldrem, J
Barrett, AJ
Venzon, D
Rick, ME
机构
[1] NCI, DCS, Pathol Lab,Div Clin Sci, Flow Cytometry Unit,NIH, Bethesda, MD 20892 USA
[2] NCI, Lab Pathol, Div Clin Sci, NIH, Bethesda, MD 20892 USA
[3] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA
[4] NIH, Warren Grant Magnuson Clin Ctr, Hematol Serv, Bethesda, MD 20892 USA
关键词
D O I
10.1182/blood.V98.4.979
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The myelodysplastic syndromes (MDSs) are characterized by bilineage or trilineage dysplasia. Although diagnostic criteria are well established for MDS, a significant number of patients have blood and bone marrow findings that make diagnosis and classification difficult. Flow cytometric immunophenotyping is an accurate and highly sensitive method for detection of quantitative and qualitative abnormalities in hematopoietic cells. Flow cytometry was used to study hematopoietic cell populations in the bone marrow of 45 patients with straightforward MDS. The results were compared with those obtained in a series of patients with aplastic anemia, healthy donors, and patients with a history of nonmyeloid neoplasia in complete remission. The immunophenotypic abnormalities associated with MDS were defined, and the diagnostic utility of flow cytometry was compared, with morphologic and cytogenetic evaluations in 20 difficult cases. Although morphology and cytogenetics were adequate for diagnosis in most cases, flow cytometry could detect immunophenotypic abnormalities in cases when combined morphology and cytogenetics were nondiagnostic. It is concluded that flow cytometric immunophenotyping may help establish the diagnosis of MDS, especially when morphology and cytogenetics are indeterminate. (C) 2001 by The American Society of Hematology.
引用
收藏
页码:979 / 987
页数:9
相关论文
共 20 条
[1]  
[Anonymous], 1997, Lab Hematol
[2]   Increasing incidence of myelodysplastic syndromes: Real or fictitious? [J].
Aul, C ;
Germing, U ;
Gattermann, N ;
Minning, H .
LEUKEMIA RESEARCH, 1998, 22 (01) :93-100
[3]  
Barrett J, 2000, SEMIN HEMATOL, V37, P15
[4]  
BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
[5]   APASTIC ANEMIA AND THE HYPOCELLULAR MYELODYSPLASTIC SYNDROME - HISTOMORPHOLOGICAL, DIAGNOSTIC, AND PROGNOSTIC FEATURES [J].
FOHLMEISTER, I ;
FISCHER, R ;
MODDER, B ;
RISTER, M ;
SCHAEFER, HE .
JOURNAL OF CLINICAL PATHOLOGY, 1985, 38 (11) :1218-1224
[6]  
Fukushima PI, 1996, CYTOMETRY, V26, P243, DOI 10.1002/(SICI)1097-0320(19961215)26:4<243::AID-CYTO2>3.0.CO
[7]  
2-D
[8]   CLONAL KARYOTYPE ABNORMALITIES AND CLINICAL-PROGRESS IN THE MYELODYSPLASTIC SYNDROME [J].
GEDDES, AD ;
BOWEN, DT ;
JACOBS, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1990, 76 (02) :194-202
[9]  
HENSEN IM, 1994, BRIT J HAEMATOL, V87, P477
[10]   ISSUES IN THE PATHOLOGY OF THE MYELODYSPLASTIC SYNDROMES [J].
KAMPMEIER, P ;
ANASTASI, J ;
VARDIMAN, JW .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1992, 6 (03) :501-522